Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 5Stomach Neoplasms 4Advanced Gastric Cancer 3Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Respiratory Tract Diseases 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lung Diseases 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Liver Neoplasms 1Hepatic Metastasis of Colorectal Cancer 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1Colorectal Cancer Recurrent 1Biliary Tract Neoplasms 1Advanced Triple Negative Breast Cancer 1Advanced Solid Tumors 1

Interventions

camrelizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Colorectal Cancer Recurrent × apatinib × Clear all
NCT04067986 2020-09-29

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Zhongshan Hospital Xiamen University

Phase 1/2 Unknown
62 enrolled
Gastrointestinal

Colorectal Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡